+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
P

Actively Recruiting

Researchers are evaluating HB0036, a drug being studied for patients with advanced solid tumors, including non-small cell lung cancer NSCLC. This Phase III, open-label, multicenter trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and effectiveness of HB0036. The study includes patients with locally advanced, recurrent, or metastatic solid tumors who have not responded to standard treatments. A Safety Review Committee will monitor safety data throughout the trial. Participants receive HB0036 through intravenous infusion every three weeks. The study is divided into two phases Phase I focuses on safety and tolerability, while Phase II evaluates safety and efficacy at the recommended Phase II dose in specific tumor groups, including NSCLC and other solid tumors. The study may adjust dosing schedules or include additional tumor types based on safety findings. During the study, participants undergo evaluations including tumor assessments by CT or MRI scans, blood tests to monitor organ function, and performance status checks. Researchers will measure safety and tolerability for up to 12 months and determine the maximum tolerated dose for up to 24 months. Pharmacokinetic parameters such as drug exposure and concentration will also be monitored. Total participation duration varies by patient condition and response.

Age: 18Years +All GendersPhase 1Phase 2
4 locations
S

Actively Recruiting

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and pharmacokinetics of INV-1120 alone and in combination with pembrolizumab in adult patients with advanced solid tumors. This phase 1, open-label, dose-escalation study aims to determine the maximum tolerated dose MTD, recommended phase 2 dose RP2D, and dose-limiting toxicities DLT of INV-1120 as a single agent or combined with pembrolizumab. The trial includes patients whose tumors have progressed after standard therapies or have no standard treatment options. In Phase 1a, approximately 36 patients will receive escalating oral doses of INV-1120 once daily until unacceptable toxicity or disease progression occurs. Up to 9 additional patients may be enrolled to confirm safety at the MTDRP2D. In Phase 1b, around 36-42 patients will receive escalating and de-escalating doses of oral INV-1120 combined with pembrolizumab, administered as 200 mg intravenously on Day 1 of each 3-week cycle, until toxicity or disease progression. Safety and tolerability of the combination will be confirmed in an expanded group of 12-15 patients. Participants will undergo safety evaluations during the first treatment cycle, including assessment of dose-limiting toxicities over 21 to 28 days depending on the phase. Researchers will monitor tumor response using imaging scans and assess pharmacokinetics through blood tests. Safety will be tracked using standard criteria for adverse events. The study period for primary outcome assessment is up to 12 months, during which patients will be closely observed for response, side effects, and drug levels to inform future dosing and treatment strategies.

Age: 18Years +All GendersPhase 1
3 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.

Age: 18Years +All GendersPhase 3
590 locations
C

Actively Recruiting

Researchers are studying how well serum tumor marker directed disease monitoring works compared to the usual monitoring approach for patients with hormone receptor positive, HER2 negative metastatic breast cancer. This trial aims to see if monitoring patients with specific blood markers to decide when to perform scans leads to similar overall survival as the standard care. The study also explores healthcare costs and patient-reported anxiety and quality of life between these monitoring methods. Participants are randomly assigned to one of two groups. One group receives usual care with imaging at least every 12 weeks and tumor marker tests as decided by their doctor. The other group undergoes regular serum tumor marker tests every 4 to 8 weeks, and imaging is only done if these markers rise. Both groups continue their assigned monitoring until disease progression or up to 312 weeks. During the study, participants complete questionnaires about anxiety and quality of life. Researchers collect data on overall survival, healthcare costs, and patient experiences over various timeframes, including up to 312 weeks for survival and 102 weeks for patient-reported outcomes. Monitoring is consistent at facilities accessible to the study team, and participants are followed closely while on their assigned monitoring approach throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
723 locations
S

Actively Recruiting

Researchers are evaluating MBRC-101, an anti-EphA5 monomethyl auristatin E MMAE antibody drug conjugate, in patients with advanced metastatic solid tumors that have not responded to standard treatments. This first-in-human, open-label study includes Phase 1, Phase 1b, and Phase 2 phases to identify optimal dosing, assess safety, and evaluate preliminary clinical activity and efficacy in specific tumor types. The study is sponsored by MBrace Therapeutics and focuses on patients with no known beneficial standard care options. The study begins with Phase 1 dose escalation to find the maximum tolerated dose MTD and optimal biologically relevant doses OBRD of MBRC-101 in about 30 patients. Phase 1b involves dose expansion with approximately 60 patients across three cohorts with specific tumor types. After determining the recommended Phase 2 dose RP2D in Phase 1b, Phase 2 will enroll around 30 patients with a specific tumor type identified earlier to evaluate anti-tumor activity and safety. Safety is closely monitored throughout by a Safety Review Committee. Participants will undergo assessments including PET-CT, CT, and MRI scans evaluated by RECIST v1.1 criteria to measure response rates and disease control. Researchers will monitor treatment-emergent adverse events and dose-limiting toxicities over up to 24 months. Pharmacokinetic profiles and antibody incidence will be characterized. The study involves multiple treatment cycles with ongoing evaluations of overall response, progression-free survival, and overall survival to understand MBRC-101s effects and safety in this patient population.

Age: 18Years +All GendersPhase 1Phase 2
17 locations
E

Actively Recruiting

This trial investigates the use of IgPro20 in adults with secondary immune deficiency caused by blood cancers who have been treated with B-cell targeting CAR T-cell therapy or T-cell engager bispecific antibody therapy. The study aims to evaluate the safety, effectiveness, and how the body processes IgPro20, focusing on reducing serious bacterial infections. Participants include adults diagnosed with specific blood cancers like multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, or B-cell acute lymphoblastic leukemia who have responded to their prior therapies. Participants are divided into two groups based on their immunoglobulin G IgG levels. Those with low IgG receive a loading dose of IgPro20 under the skin daily for five days, followed by weekly doses for a year. Those with higher IgG levels and ongoing immunoglobulin therapy receive weekly IgPro20 injections for 52 weeks. The IgPro20 is given as subcutaneous infusions, and the study is open-label and conducted at multiple centers. During the study, participants will have regular visits for up to 12 months to monitor infections, hospitalizations, use of anti-infective medications, and side effects. Blood samples will be collected to measure IgG levels and pharmacokinetics. Researchers will observe the rate of serious bacterial infections as the primary outcome, along with other infection-related and safety measures. The total participation duration is approximately one year.

Age: 18Years +All GendersPhase 3
60 locations

1-10 of 14

1